Legend Biotech Corporation (FRA:9LB)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
United States of America Revenue	-	803.60M	579.05M
United States of America Revenue Growth	-	38.78%	114.55%
China Revenue	-	26.60M	320.00K
China Revenue Growth	-	8212.50%	78.77%
Europe Revenue	-	198.70M	47.87M
Europe Revenue Growth	-	315.06%	217.66%
Revenue (Total)	1.14B	1.03B	627.30M
Revenue (Total) Growth	10.68%	64.02%	120.03%

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
License Revenue	81.12M	83.80M	138.40M
License Revenue Growth	-3.20%	-39.45%	293.64%
Collaboration Revenue	1.06B	944.80M	482.58M
Collaboration Revenue Growth	11.93%	95.78%	93.18%
Other Service Revenue	-	300.00K	6.26M
Other Service Revenue Growth	-	-95.20%	3395.53%
Revenue (Other)	121.00K	-	59.00K
Revenue (Total)	1.14B	1.03B	627.30M
Revenue (Total) Growth	10.68%	64.02%	120.03%

Data Source: Fiscal.ai Last updated: Mar 31, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 25, 2026

Data Sources Report a data error